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Abstract
Background: Alpha linolenic acid (ALA) is the major omega-3 fatty acid in the diet. Evidence on health effects of ALA is not
conclusive, but some observational studies found an increased risk of prostate cancer with higher intake of ALA. We
examined the effect of ALA supplementation on serum concentrations of prostate-specific antigen (PSA), a biomarker for
prostate cancer.
Methods: The Alpha Omega Trial (ClinicalTrials.gov Identifier: NCT00127452) was a double-blind, placebo-controlled trial of
ALA and the fish fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA) on the recurrence of cardiovascular
disease, using a 262 factorial design. Blood was collected at the start and the end of the intervention period. The present
analysis included 1622 patients with a history of a myocardial infarction, aged 60–80 years with an initial PSA concentration
,4 ng/mL. They received either 2 g per day of ALA or placebo in margarine spreads for 40 months. T-tests and logistic
regression were used to assess the effects of ALA supplementation on changes in serum PSA (both continuously and as a
dichotomous outcome, cut-off point: .4 ng/mL).
Findings: Mean serum PSA increased by 0.42 ng/mL on placebo (n = 815) and by 0.52 ng/mL on ALA (n = 807), a difference
of 0.10 (95% confidence interval: 20.02 to 0.22) ng/mL (P = 0?12). The odds ratio for PSA rising above 4 ng/mL on ALA
versus placebo was 1.15 (95% CI: 0.84–1.58).
Interpretation: An additional amount of 2 g of ALA per day increased PSA by 0.10 ng/mL, but the confidence interval
ranged from 20.02 to 0.22 ng/mL and included no effect. Therefore, more studies are needed to establish whether or not
ALA intake has a clinically significant effect on PSA or prostate cancer.
Trial registration information: ClinicalTrials.gov; Identifier: NCT00127452. URL: http://www.clinicaltrials.gov/ct2/show/
NCT00127452.
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Introduction
Alpha linolenic acid (ALA, C18:3 n-3) is an essential omega-3
fatty acid and it is the precursor of the other long chain omega-3
fatty acids. Human tissues can convert ALA into the longer chain
omega-3 fatty acids eicosapentaenoic acid (EPA, C20:5 n-3) and
docosahexaenoic acid (DHA C22:6 n-3), but only to a limited
extent. [1,2] Major dietary sources of alpha-linolenic acid are
soybean oil, canola oil and walnuts. Flaxseed is particularly rich in
alpha-linolenic acid and capsules of flaxseed oil are sold as
supplements. The average dietary intake of ALA in high-income
countries is about 2 g per day. [3].
Observational studies suggest that an increased intake of alpha-
linolenic acid is associated with a moderately lower risk of
cardiovascular disease. [4] In contrast, a higher intake of alpha-
linolenic acid has also been suggested to be associated with a
higher risk of prostate cancer. Two meta-analyses that included
both prospective and case control studies found that higher intakes
of alpha-linolenic acid and higher levels in blood and adipose
tissue were associated with increased risk of prostate cancer.
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[5,6,7] Simon et al. observed that higher concentrations of ALA in
blood or adipose tissue were associated with a higher risk of
prostate cancer (relative risk [RR]= 1.54; 95% CI 1.16–2.06), but
no association was found for dietary ALA intake as assessed by
food frequency questionnaire (RR=1.09; 95% CI 0.91–1.32). [5]
Carayol et al. limited their meta-analysis to prospective studies on
dietary ALA and incident prostate cancer, and found no
association (RR=0.97; 95% CI 0.86–1.10). However, this meta-
analysis showed a small significant adverse association when
comparing high with low ALA intake categories [8] and another
large observational study that was not yet included in the meta-
analysis suggests a similar association. [9] We conclude from these
results that the association of ALA with prostate cancer is not
clear.
The Alpha Omega Trial was a double-blind placebo-controlled
trial in 60–80 year-old patients with a history of myocardial
infarction who received moderate additional amounts of omega-3
fatty acids for the prevention of recurrent cardiovascular diseases.
The incidence of prostate cancer was monitored as a potential
adverse effect in this study. [10,11] ALA supplementation was not
related to the incidence of prostate cancer. However, there were
only 42 incident prostate cancer cases and thus the power to detect
an effect was low. [10,11] Serum concentrations of prostate
specific antigen (PSA), a serine protease produced by prostatic
epithelial cells [12], are often elevated in men with prostate cancer
(www.cancer.gov/cancertopics/factsheets/detection/PSA). High
concentrations may predict long-term increases in prostate cancer
incidence and mortality. [13] Here we report the effect of an
additional amount of ALA of 2 grams daily on serum PSA
concentrations in older patients who had suffered a myocardial
infarction and had participated in the Alpha Omega Trial. [11].
Methods
Study Population
The Alpha Omega Trial has been described in detail
previously. [10,11] The protocol for this trial and supporting
CONSORT checklist are available as supporting information;
see Checklist S1 and Protocol S1. The participants were 3783
men and 1054 women who had suffered a myocardial infarction
10 years or less prior to randomization. The present study was
limited to 2278 men randomized before August 2005 (Figure 1).
We did not collect final blood samples for men randomized
after that date because of a lack of funds. We excluded data of
men who had prostate cancer at baseline or who used
androgenic or anti-androgenic medication, who died during
the intervention period, who refused final examinations, or for
whom not enough blood was available. We only included
patients with a baseline PSA concentration ,4 ng/mL, because
patients with a PSA level above 4 ng/mL have a high chance
of having undiagnosed prostate cancer (21.3%) or of having
hyperplasia or prostatitis; this may influence the effect of alpha
linolenic acid on PSA. [13] This left a study population of 1622
men (Figure 1). The patients provided written informed consent.
The trial was approved by a central medical ethics committee
(Haga Hospital Leyenburg, The Hague, The Netherlands) and
by local ethics committees of participating hospitals.
Intervention with Omega-3 Fatty Acids
The patients were randomly assigned to receive trial margarines
according to a 2-by-2 factorial design, for 40 months. For logistical
reasons, all patients received a placebo margarine during the first
4–6 weeks after randomization. After this period the patients
received either approximately 2 g ALA per day, or 400 mg EPA
and DHA, or both, or a placebo with no omega-3 fatty acids. [10]
The additional amount of ALA corresponded with the recom-
mended dietary allowance. [3] In the trial margarines for the
active treatment groups, the various omega-3 fatty acids replaced
an equivalent amount of oleic acid in the margarine. Subjects were
asked to consume approximately 20 grams of margarine per day.
Margarines were identical in taste, texture, color, and odor. An
objective measure of adherence was obtained by determining the
proportions of fatty acids in plasma cholesteryl esters in a random
subgroup of 217 male patients at baseline, 211 at 20 months and
523 at 40 months. [10].
Data Collection and Follow-up Procedures
The patients underwent physical examinations by trained
research nurses at baseline and after 40 months. Patients filled
out questionnaires about demographic factors, lifestyle character-
istics, medications and medical history. The definition of diabetes
was based on a physician diagnosis, and/or the use of antidiabetic
drugs and/or elevated plasma glucose levels. Obesity was defined
as Body Mass Index (kg/m2).30.
Blood samples were obtained at the subjects’ home or at a
hospital. Tubes were sent via standard postal service to a central
laboratory. In a pilot study on 76 patients, [10] 89% of blood
samples was delivered within 24 h and 96% within 48 h. Serum
was stored at 280uC for a maximum of 8 year. After the study
had been completed we measured total PSA concentrations with
an immunometric assay (Architect, Abbott Diagnostics, Abbott
Park, Illinois USA) at the endocrine laboratory of VU
University Amsterdam medical center. Laboratory personnel
was blinded to the treatment groups. The detection limit was
0?1 ng/mL, the intra-assay coefficient of variation at a PSA
level of 0.5, 4 and 25 ng/mL was 5%, 3% and 4%,
respectively, and the inter-assay coefficient of variation 8%,
6%, and 6%, respectively.
Statistical Analysis
Data were analyzed according to a predefined statistical analysis
plan. The two groups that received ALA were combined (n= 807)
and compared with the two groups that did not receive ALA
(n= 815). The primary endpoints were the change in serum PSA
during the 40-month intervention period (continuously) and the
progression from PSA #4 ng/mL to PSA .4 ng/mL.
Differences in changes of PSA between treatments were assessed
with two-sided t-tests for independent samples. We also stratified
that analysis for treatment with EPA/DHA (yes/no). Our study
did not have the objective to investigate the effect of EPA plus
DHA, but we show the outcomes for completeness. The
dichotomous outcome of progression to PSA level .4 ng/mL
(yes/no) was analyzed by logistic regression. PSA velocity is
frequently used for monitoring the risk of prostate cancer. [14,15]
In a post-hoc analysis, we calculated the additional outcome of
PSA velocity defined as change in PSA per year, which was
categorized using different cut-off points (.0.50, .0.75 and
.1.00 ng/mL). The odds ratio for different PSA velocities
between the combined ALA group and the combined placebo
group were also calculated by logistic regression. SPSS software
version 17.0 was used for all analyses.
Results
Descriptive Data
Baseline characteristics were similar among treatment groups
for the 1622 men with an initial PSA level at or below 4
ng/mL (Table 1). The mean age of the patients was 68.0 y,
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20.7% was obese and 17.5% had diabetes, 16.6% smoked and
78% used at least one alcoholic drink per week. Their median
PSA-level was 1.09 (25th to 75th percentile = 0.61 to 1.97) ng/
mL at entry.
The average intake of trial margarine was 20.2 (SD: 3.5) grams
per day and 97% of the participants consumed the margarine at
least 80% of the time. The patients received on average an
additional amount of 2 g of ALA per day. A high adherence was
confirmed by the proportion of ALA in plasma cholesteryl esters,
which increased by 65% after 20 months and 67% after 40 months
in the ALA relative to the placebo group (Figure 2).
Figure 1. Participant flow for the study on effect of alpha linolenic acid (ALA) supplementation on PSA in post myocardial patients
in the Alpha Omega Trial.
doi:10.1371/journal.pone.0081519.g001
Table 1. Baseline characteristics of 1622 male patients of the Alpha Omega Trial who were included in the study on PSA change,
by treatment group*.
Placebo EPA-DHA ALA ALA+EPA-DHA
N=423 N=392 N=410 N=397
Age (yr) 67?865?1 68?265?2 68?165?4 68?065?1
Body Mass Index (kg/m2) 27?763?7 27?663?2 27?563?1 27?563?2
Obese* (%) 22?0 21?9 19?3 19?4
Diabetic{ (%) 19?4 16?6 16?6 17?4
Intermediate or higher education` (%) 47?6 41?7 44?3 46?5
Smoking status
Never (%) 9?9 16?1 12?7 11?1
Former (%) 73?3 67?3 69?5 73?5
Current (%) 16?8 16?6 17?8 15?4
Alcohol use
$1 glass/wk (%) 79?0 78?3 76?3 78?5
,1 glass/wk or past drinker (%) 16?5 16?8 18?1 14?4
Never (%) 4?5 4?8 5?6 7?1
Serum Prostate Specific Antigen (ng/mL) 1?3760?96 1?3761?01 1?4260?97 1?4360?97
Data are reported as mean 6 standard deviation (SD) or percentages (%).ALA = alpha linolenic acid, EPA = eicosapentanoic acid = EPA, DHA=docosahexanoic acid.
*Subjects with initial PSA concentrations .4 ng/mL (n = 255) were excluded, see Methods and Figure 1.
**Body mass index $30 kg/m2.
{Self-reported diabetes diagnosed by a physician and/or treatment with antidiabetic medication and/or elevated plasma glucose level.
`High school at intermediate or higher level, or higher vocational education college or university.
doi:10.1371/journal.pone.0081519.t001
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Effect of ALA Supplementation on Serum PSA
Mean serum PSA increased by 0.52 (95% CI: 0.41 to 0.62)
ng/mL in the combined ALA group compared to 0.42 (0.35 to
0.48) ng/mL in the combined placebo group during the
intervention, an increase of 0.10 (20.02 to 0.22) ng/mL
(P= 0.12; Figure 3). There was no indication for an interaction
between ALA and EPA/DHA For the two comparisons of ALA
versus placebo the test of heterogeneity was non-significant
(Q-value 0.054; I-squared 0.000; P = 0.82), similar to the
comparisons of EPA-DHA vs. placebo (Q-value 0.052; I-squared
0.000; P = 0.82). A similar increase (0.11; 20.09 to 0.32 ng/mL)
as in the combined groups was obtained for the patients in the
group that received only ALA compared with the pure placebo
group. Receiving EPA/DHA decreased mean serum PSA by 0.12
(20.25 to 0.00) ng/mL compared with receiving placebo
(Figure 3).
The risk of changing from a PSA ,4 ng/mL to a PSA .4
ng/mL was increased by 15% (odds ratio 1.15; 95% CI 0.84 to
1.58) for ALA compared to placebo treatment (Table 2). Only one
man with a baseline PSA value below 4 ng/mL was diagnosed
with prostate cancer during the 40 mo of follow-up. His PSA value
exceeded 4 ng/mL at the end of the study. We combined his data
with those of 173 patients who also reached a PSA level above
4 ng/mL during the trial. ALA supplementation increased PSA
velocity, but the 95% confidence intervals of the odds ratios in
different categories of PSA velocity included 1.
Discussion
Supplementation with an additional amount of 2 gram ALA per
day during 40 months increased serum PSA concentrations of
older post-myocardial infarction patients by 0.10 ng/mL. How-
ever, the 95% confidence interval ranged from 20.02 to 0.22
mg/mL. Effects of ALA supplementation on PSA velocity and on
the combined endpoint of prostate cancer and a PSA level above
4 ng/mL were in the direction of a raising effect, but the
confidence intervals were wide and all included 1.
To our knowledge, this is the first large-scale clinical trial that
investigated the effect of ALA on serum PSA. The major limitation
of our study was that we did not have enough prostate cancer cases
to test the hypothesis that ALA supplementation increases the risk
of this clinical outcome. It is important to realize that an effect on
PSA cannot be translated one to one into an effect on prostate
cancer. Serum PSA is a sensitive predictor of prostate cancer [16]
but it is also increased in men with prostatitis and benign prostatic
hyperplasia because PSA reflects prostate tissue volume. PSA
levels .4.0 ng/mL do not always indicate a higher risk of cancer;
only 25–33 percent of men with PSA .4.0 ng/mL indeed have
prostate cancer. [17].
Another limitation is that we tested the hypothesis that ALA
supplementation increases the serum PSA level in older patients
who have had a myocardial infarction. This limits the generaliza-
tion of the results of our trial to the general older male population
or to younger men. We excluded men who died during the trial,
who had prostate cancer or a PSA level above 4 at baseline, who
refused final examination, or for whom we had insufficient blood
(see figure 1). On average the patients in our sample were
therefore slightly healthier than the full cohort. However, we do
not expect that had a major impact on our outcomes because
treatment groups were quite similar at baseline (Table 1). Thus, we
consider bias from differential prognosis in the four groups
unlikely. Strengths of the trial were that the compliance to ALA
supplementation was excellent and the additional amount of
2 gram ALA per day was realistic and of the same size as the
recommended dietary allowance. Also the follow-up of 40 months
was longer than in other trials and allowed us to study the long-
term effects of ALA supplementation on serum PSA.
Our results should be very carefully interpreted as the observed
95% confidence interval ranges from 20.02 to 0.22 ng/mL. This
range includes zero, i.e. no effect. However, it also includes
clinically meaningful effects. In the Copenhagen City Heart Study
[13], men aged .60 yrs had a 10-year prostate cancer risk of
approximately 1.1%, if their PSA between 0.01 and 1.00 ng/mL
and the risk was 3.6% for men with a PSA between 1.01 and
2.00 ng/mL. Thus, in this range, a 1 ng/mL higher PSA level was
associated with a 2.5% higher absolute 10-year prostate cancer
incidence risk. Extrapolation from the Copenhagen City Heart
Study [13] suggests that the observed mean increase in PSA of
0.10 ng/mL could lead to one extra new case of prostate cancer
per 400 older men in 10 years. The upper limit of the confidence
interval was 0.22 ng/mL, and such a rise could lead to one extra
case per 180 men. When millions of men eat foods high in ALA
they could easily reach the 2 g of ALA/d supplemented in our
trial, and then the numbers start to add up. This reasoning is,
however, highly speculative because it assumes a causal relation
between the ALA-induced rise of PSA and prostate cancer
incidence.
Figure 2. Alpha linolenic acid (ALA) concentrations in plasma
cholesteryl esters at baseline, after 20 months and after 40
months, in random samples of post-MI patients, according to
treatment group. Geometric mean values (expressed as mass
percentage) on a logarithmic scale are given, with error bars indicating
standard errors. After 20 and 40 months, ALA supplementation in the
margarine increased serum ALA by 64?7% and 66?9% as compared with
placebo. *P,0?001 for group difference at that time point, obtained by
t-test for independent samples.
doi:10.1371/journal.pone.0081519.g002
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As far as we know we are the first to investigate the effect of pure
alpha-linolenic acid by itself on PSA in men without prostate
cancer. However, an earlier small study investigated the effect of
flaxseed supplementation on prostate cancer proliferation rates
and PSA in men with prostate cancer. [18] Flaxseed is a rich
source of alpha-linolenic acid. Although patients with prostate
cancer are quite different from our population and the study was
small it should be noted that they did not show an effect on PSA
and even showed a reduction in prostate cancer proliferation rates.
[18].
The average dietary intake of ALA is approximately 2 g per day
in men aged 50 to 70 yrs in The Netherlands. [19] In our trial we
provided another 2 g which increased the total intake to about
4 g/d. Habitual intakes of 4 grams or more per day are rare, [19]
but supplements rich in ALA can easily increase intake by 2 to
3 g/d, especially if people take teaspoons of flaxseed oil (linseed oil)
daily. We observed a mean increase of 0.1 ng/mL in serum PSA
concentrations after 40 months of supplementation with 2 g ALA
per day, but confidence interval were too wide for definitive
conclusions. Therefore, more trials are needed to investigate the
effects of additional doses of 2–4 gram ALA per day.
Figure 3. Effect of ALA supplementation on prostate specific antigen (PSA) concentrations (ng/mL) of 1622 male patients. Values are
means (95% confidence interval). ALA= alpha linolenic acid, EPA= eicosapentanoic acid = EPA, DHA=docosahexanoic acid. For the two comparisons
of ALA vs. placebo the test of heterogeneity was non-significant (Q-value 0.054; I-squared 0.000; P = 0.82), similar to the comparisons of EPA-DHA vs.
placebo (Q-value 0.052; I-squared 0.000; P = 0.82).
doi:10.1371/journal.pone.0081519.g003
Table 2. Risk of reaching a serum PSA concentration .4 ng/mL or an increased PSA-velocity after 40 months of ALA
supplementation.
ALA* Placebo{ Odds ratio (95% CI) P-value`
N=807 N=815
Final PSA .4 ng/mL 92 82 1?15 (0?84–1?58) 0?38
PSA Velocity
.0?50 ng/mL per year 68 54 1?30 (0?90–1?88) 0?17
.0?75 ng/mL per year 40 26 1?58 (0?96–2?62) 0?07
.1?00 ng/mL per year 23 12 1?96 (0?97–3?97) 0?06
PSA=prostate specific antigen), PSA Velocity = change in serum PSA concentrations per year, ALA = alpha linolenic acid, EPA = eicosapentanoic acid = EPA,
DHA=docosahexanoic acid.
*410 subjects treated with alpha linolenic acid alone plus 397 subjects treated with alpha linolenic acid plus EPA/DHA.
{423 subjects treated with placebo alone plus 392 subjects treated with EPA/DHA alone.
`P-value t-test (two-sided).
doi:10.1371/journal.pone.0081519.t002
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The present study suggests that an additional amount of 2 g
ALA per day may increase serum PSA, but it is unclear if and how
ALA could influence prostate carcinogenesis. Sparse evidence
from animal and cell structure studies suggests that ALA might act
through other pathways than the very-long chain omega-3 fatty
acids from fish fatty acids (eicosapentanoic acid and docosahex-
anoic acid). These have been claimed to be protective in the
multistep process of carcinogenesis. [20,21] Our study did not
have the objective to investigate the effect of these longer chain n-3
fatty acids. However, the effect of the EPA/DHA group versus
placebo was in the direction of a protective effect (20.12; 95% CI
20.25 to 0.00 ng/mL). Two studies that investigated effects of
intervention with the longer chain n-3 fatty acids found either no
effect [22] or a protective effect [23]. In contrast, a large
prospective case cohort study indicates an increased prostate
cancer risk for men with high blood concentrations of longer chain
n-3 fatty acids [24]. Therefore, effects of longer n-3 fatty acids on
prostate cancer risk remain unclear.
In conclusion, an additional amount of 2 g ALA per day did
increase the PSA concentration by 0.1 ng/mL, but the confidence
interval ranged from a nil finding to a clinically meaningful effect.
More research is needed to find out whether ALA influences the
serum PSA level and the risk of prostate cancer and which levels of
ALA intake are optimal for human health.
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